{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for amphotericin root_codes_comments in Code Comments (approximate match)
Status:
US Previously Marketed
Source:
REZULIN by PFIZER PHARMS
(1997)
Source URL:
First approved in 1997
Source:
REZULIN by PFIZER PHARMS
Source URL:
Class:
MIXTURE
Troglitazone (TGZ, brand name: Rezulin and Prelay) is a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, which was developed by Daiichi Sankyo and approved for the US market for the treatment of Type II diabetes mellitus. The drug is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise, and was not indicated as initial therapy in patients with type 2 diabetes. This drug was withdrawn from the UK market due to liver toxicity. It was removed from the US market in 2000, only 3 years after its introduction and from Japan, shortly afterward. In addition, was conducted a clinical trial for the treatment of patients with advanced liposarcoma by using troglitazone, but the positive result wasn’t obtained. It was shown, that in case of cancer cells troglitazone acted independently of PPAR gamma, by up-regulation of early growth response-1 (Egr-1). Egr-1 transcription factor has been linked to apoptosis and shown to be activated by extracellular signal-regulated kinase (ERK).
Status:
First approved in 1962
Class:
MIXTURE
Status:
First approved in 1953
Class:
MIXTURE
Targets:
Conditions:
Carbomycin is a complex mixture containing carbomycin A with a small portion of carbomycin B. Carbomycin is produced by Streptomyces halstedii and acts as an antibiotic. The drug was approved by FDA under the name Magna-terramycin (in combination with oxytetracycline) for the treatment of bacterial chronic respiratory diseases in chickens. Carbomycin exerts its antibacterial action by binding within the large ribosomal subunit and thus inhibiting the protein synthesis in bacterias.
Status:
First approved in 1951
Class:
MIXTURE
Status:
US Previously Marketed
Source:
DEPINAR by ARMOUR PHARM
(1960)
Source URL:
First marketed in 1921
Class:
MIXTURE
Targets:
Tannic acid (TA) is a naturally occurring plant-derived polyphenol found in several herbaceous and woody plants, wines and a broad selection of teas. TA has strong antioxidant/free radical scavenging, anti-inflammatory, anti-viral/bacterial, and anti-carcinogenic properties. The neuroprotective effects of TA against Alzheimer’s disease (AD) have been shown in several in vitro and in vivo models of AD. Evidence suggests that TA is a natural inhibitor of β-secretase (BACE1) activity and protein expression. BACE1 is the primary enzyme responsible for the production and deposition of Aβ peptide. TA can also inhibit the in vitro aggregation of tau peptide, a core component of intracellular neurofibrillary tangles (NFTs). In addition, combination of tannic acid with eucalyptus Oil and Allantoin (from Comfrey) is known as homeopathic product which is used to temporarily relieve the aches and pains of muscles and joints associated with: arthritis, simple backache, strains, bruises, sprains.
Status:
US Previously Marketed
First marketed in 1921
Class:
MIXTURE
Status:
US Previously Marketed
Source:
Purified Siliceous Earth U.S.P.
(1921)
Source URL:
First marketed in 1921
Source:
Purified Siliceous Earth U.S.P.
Source URL:
Class:
MIXTURE
Status:
US Previously Marketed
First marketed in 1921
Class:
MIXTURE
Status:
US Previously Marketed
Source:
Amyl Nitrite U.S.P.
(1880)
Source URL:
First marketed in 1880
Source:
Amyl Nitrite U.S.P.
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
First approved in 2024
Source:
M016
Source URL:
Class:
MIXTURE